Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy
about
Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Eligibility for alirocumab or ...... L-cholesterol-lowering therapy
@en
type
label
Eligibility for alirocumab or ...... L-cholesterol-lowering therapy
@en
prefLabel
Eligibility for alirocumab or ...... L-cholesterol-lowering therapy
@en
P2093
P2860
P356
P1476
Eligibility for alirocumab or ...... L-cholesterol-lowering therapy
@en
P2093
Ashwin Kumar
Charles J Glueck
Ishan Anand
Marloe Prince
Michael Goldenberg
Naila Goldenberg
Vybhav Jetty
P2860
P304
P356
10.2147/VHRM.S133690
P407
P577
2017-07-06T00:00:00Z